Mapping the differences in care for 5,000 Spinal Muscular Atrophy patients, a survey of 24 national registries in North America, Australasia and Europe
- 27 October 2013
- journal article
- research article
- Published by Springer Nature in Journal of Neurology
- Vol. 261 (1) , 152-163
Abstract
Spinal muscular atrophy (SMA) is an autosomal recessive genetic disorder characterised by the degeneration of motor neurons and progressive muscle weakness. It is caused by homozygous deletions in the survival motor neuron gene on chromosome 5. SMA shows a wide range of clinical severity, with SMA type I patients often dying before 2 years of age, whereas type III patients experience less severe clinical manifestations and can have a normal life span. Here, we describe the design, setup and utilisation of the TREAT-NMD national SMA patient registries characterised by a small, but fully standardised set of registry items and by genetic confirmation in all patients. We analyse a selection of clinical items from the SMA registries in order to provide a snapshot of the clinical data stratified by SMA subtype, and compare these results with published recommendations on standards of care. Our study included 5,068 SMA patients in 25 countries. A total of 615 patients were ventilated, either invasively (178) or non-invasively (437), 439 received tube feeding and 455 had had scoliosis surgery. Some of these interventions were not available to patients in all countries, but differences were also noted among high-income countries with comparable wealth and health care systems. This study provides the basis for further research, such as quality of life in ventilated SMA patients, and will inform clinical trial planning.Keywords
This publication has 18 references indexed in Scilit:
- Spinal muscular atrophyOrphanet Journal of Rare Diseases, 2011
- Characterization of the DMD/BMD patient population in Czech Republic and Slovakia using an innovative registry approachNeuromuscular Disorders, 2009
- Consensus Statement for Standard of Care in Spinal Muscular AtrophyJournal of Child Neurology, 2007
- Genetic risk assessment in carrier testing for spinal muscular atrophyAmerican Journal of Medical Genetics, 2002
- Quantitative Analyses of SMN1 and SMN2 Based on Real-Time LightCycler PCR: Fast and Highly Reliable Carrier Testing and Prediction of Severity of Spinal Muscular AtrophyThe American Journal of Human Genetics, 2002
- SMN gene duplication and the emergence of the SMN2 gene occurred in distinct hominids: SMN2 is unique to Homo sapiensHuman Genetics, 2001
- Correlation between severity and SMN protein level in spinal muscular atrophyNature Genetics, 1997
- Identification and characterization of a spinal muscular atrophy-determining geneCell, 1995
- Mapping of acute (type I) spinal muscular atrophy to chromosome 5q12-q14The Lancet, 1990
- Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q1 1.2–13.3Nature, 1990